Recurrent Miscarriage
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Adenomyosis in Infertile Women: Prevalence and the Role of 3D Ultrasound As a Marker of Severity of the Disease J
Puente et al. Reproductive Biology and Endocrinology (2016) 14:60 DOI 10.1186/s12958-016-0185-6 RESEARCH Open Access Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease J. M. Puente1*, A. Fabris1, J. Patel1, A. Patel1, M. Cerrillo1, A. Requena1 and J. A. Garcia-Velasco2* Abstract Background: Adenomyosis is linked to infertility, but the mechanisms behind this relationship are not clearly established. Similarly, the impact of adenomyosis on ART outcome is not fully understood. Our main objective was to use ultrasound imaging to investigate adenomyosis prevalence and severity in a population of infertile women, as well as specifically among women experiencing recurrent miscarriages (RM) or repeated implantation failure (RIF) in ART. Methods: Cross-sectional study conducted in 1015 patients undergoing ART from January 2009 to December 2013 and referred for 3D ultrasound to complete study prior to initiating an ART cycle, or after ≥3 IVF failures or ≥2 miscarriages at diagnostic imaging unit at university-affiliated private IVF unit. Adenomyosis was diagnosed in presence of globular uterine configuration, myometrial anterior-posterior asymmetry, heterogeneous myometrial echotexture, poor definition of the endometrial-myometrial interface (junction zone) or subendometrial cysts. Shape of endometrial cavity was classified in three categories: 1.-normal (triangular morphology); 2.- moderate distortion of the triangular aspect and 3.- “pseudo T-shaped” morphology. Results: The prevalence of adenomyosis was 24.4 % (n =248)[29.7%(94/316)inwomenaged≥40 y.o and 22 % (154/ 699) in women aged <40 y.o., p = 0.003)]. Its prevalence was higher in those cases of recurrent pregnancy loss [38.2 % (26/68) vs 22.3 % (172/769), p < 0.005] and previous ART failure [34.7 % (107/308) vs 24.4 % (248/1015), p < 0.0001]. -
The Role of Endometrial Stem Cells in Recurrent Miscarriage
REPRODUCTIONREVIEW Success after failure: the role of endometrial stem cells in recurrent miscarriage Emma S Lucas1,2, Nigel P Dyer3, Katherine Fishwick1, Sascha Ott2,3 and Jan J Brosens1,2 1Division of Biomedical Sciences, Warwick Medical School, Coventry, UK, 2Tommy’s National Centre for Miscarriage Research, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK and 3Warwick Systems Biology Centre, University of Warwick, Coventry, UK Correspondence should be addressed to J Brosens; Email: [email protected] Abstract Endometrial stem-like cells, including mesenchymal stem cells (MSCs) and epithelial progenitor cells, are essential for cyclic regeneration of the endometrium following menstrual shedding. Emerging evidence indicates that endometrial MSCs (eMSCs) constitute a dynamic population of cells that enables the endometrium to adapt in response to a failed pregnancy. Recurrent miscarriage is associated with relative depletion of endometrial eMSCs, which not only curtails the intrinsic ability of the endometrium to adapt to reproductive failure but also compromises endometrial decidualization, an obligatory transformation process for embryo implantation. These novel findings should pave the way for more effective screening of women at risk of pregnancy failure before conception. Reproduction (2016) 152 R159–R166 Introduction Successful implantation of a human embryo is commonly date (Fragouli et al. 2013), each implanting blastocyst attributed to binary variables; i.e. nidation of a ‘normal’, is arguably unique. Furthermore, transient aneuploidy but not an ‘abnormal’, embryo in a ‘receptive’, but during development may not be unequivocally as not a ‘non-receptive’, endometrium is required for ‘bad’ as has been intuitively presumed because of the a successful pregnancy. -
Congenital Uterine Anomalies: the Role of Surgery Maria Carolina Fernandes Lamouroux Barroso M 2021
MESTRADO INTEGRADO EM MEDICINA Congenital uterine anomalies: the role of surgery Maria Carolina Fernandes Lamouroux Barroso M 2021 Congenital uterine anomalies: the role of surgery Dissertação de candidatura ao grau de Mestre em Medicina, submetida ao Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto Maria Carolina Fernandes Lamouroux Barroso Aluna do 6º ano profissionalizante de Mestrado Integrado em Medicina Afiliação: Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto Endereço: Rua de Jorge Viterbo Ferreira nº228, 4050-313 Porto Endereço eletrónico: [email protected]; [email protected] Orientador: Dra. Márcia Sofia Alves Caxide e Abreu Barreiro Diretora do Centro de Procriação Medicamente Assistida e do Banco Público de Gâmetas do Centro Materno-Infantil do Norte Assistente convidada, Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto. Afiliação: Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto Endereço: Largo da Maternidade de Júlio Dinis 45, 4050-651 Porto Endereço eletrónico: [email protected] Coorientador: Prof. Doutor Hélder Ferreira Coordenador da Unidade de Cirurgia Minimamente Invasiva e Endometriose do Centro Materno- Infantil do Norte Professor associado convidado, Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto. Afiliação: Instituto de Ciências Biomédicas Abel Salazar – Universidade do Porto Endereço: Rua Júlio Dinis 230, B-2, 9º Esq, Porto Endereço eletrónico: [email protected] Junho 2021 Porto, junho de 2021 ____________________________________ (Assinatura da estudante) ____________________________________ (Assinatura da orientadora) ____________________________________ (Assinatura do coorientador) ACKNOWLEDGEMENTS À Dra. Márcia Barreiro, ao Dr. Luís Castro e ao Prof. Doutor Hélder Ferreira, por toda a disponibilidade e empenho dedicado à realização deste trabalho. Aos meus pais, irmão e avós, pela participação que desde sempre tiveram na minha formação, e pelo carinho e apoio incondicional. -
Recurrent Miscarriage
Elizabeth Taylor, MD, FRCSC, Mohammed Bedaiwy, MD, PhD, Mahmoud Iwes, MD Recurrent miscarriage Management of pregnancy loss includes investigating causes, addressing modifiable risk factors, and providing supportive care in the first trimester of pregnancy. ABSTRACT: Early miscarriages are arly miscarriage has been re Genetic causes those occurring within the first 12 ported to occur in 17% to 31% The risk of miscarriage increases completed weeks of gestation. Re- E of pregnancies,1,2 and is de with maternal age. At age 20 to 24 current miscarriage, defined as two fined as a nonviable intrauterine the risk is approximately 10%, with or more consecutive pregnancy loss- pregnancy with either an empty ges risk increasing to nearly 80% by age es, affects 3% of couples trying to tational sac or a gestational sac con 45.5 The relationship between mis conceive and can cause consider- taining an embryo or fetus without carriage risk and maternal age can be able distress. The risk of miscarriage fetal heart activity within the first explained by the increasing rate of oo increases with maternal age. Genet- 12 completed weeks of gestation.3 cyte aneuploidy that occurs as women ic abnormalities, uterine anomalies, Recurrent miscarriage occurs in 3% grow older. In one study, oocytes and endocrine dysfunction can all of couples trying to conceive. The examined during in vitro fertilization lead to miscarriage. Other causes of American Society for Reproductive (IVF) treatment had only a 10% risk miscarriage are autoimmune disor- Medicine (ASRM) defines recurrent of being aneuploid in women younger ders such as antiphospholipid syn- miscarriage as two or more failed than age 35, but by age 43 the risk of drome and chronic endometritis. -
Development and Validation of a Model for Individualized Prediction
Wu et al. Reproductive Biology and Endocrinology (2021) 19:6 https://doi.org/10.1186/s12958-020-00693-x RESEARCH Open Access Development and validation of a model for individualized prediction of cervical insufficiency risks in patients undergoing IVF/ICSI treatment Yaoqiu Wu1,2, Xiaoyan Liang1, Meihong Cai3, Linzhi Gao1, Jie Lan2 and Xing Yang1* Abstract Background: Women who conceived with in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) are more likely to experience adverse pregnancy outcomes than women who conceived naturally. Cervical insufficiency (CI) is one of the important causes of miscarriage and premature birth, however there is no published data available focusing on the potential risk factors predicting CI occurrence in women who received IVF/ICSI treatment. This study aimed to identify the risk factors that could be integrated into a predictive model for CI, which could provide further personalized and clinically specific information related to the incidence of CI after IVF/ICSI treatment. Patients and methods: This retrospective study included 4710 patients who conceived after IVF/ICSI treatment from Jan 2011 to Dec 2018 at a public university hospital. The patients were randomly divided into development (n = 3108) and validation (n = 1602) samples for the building and testing of the nomogram, respectively. Multivariate logistic regression was developed on the basis of pre-pregnancy clinical covariates assessed for their association with CI occurrence. Results: A total of 109 patients (2.31%) experienced CI among all the enrolled patients. Body mass index (BMI), basal serum testosterone (T), gravidity and uterine length were associated with CI occurrence. The statistical nomogram was built based on BMI, serum T, gravidity and uterine length, with an area under the curve (AUC) of 0.84 (95% confidence interval: 0.76–0.90) for the developing cohort. -
Fallopian Tubes
Joy of GettinG PreGnant Your Complete Guide To Overcome Infertility author / editor / Copyright © Dr. Rupal N. Shah, M.D., D.G.O., Diploma in Reproductive Medicine (Kiel), Germany Contact: [email protected] Publisher: Pugmarks Mediaa, 119, Swami Vivekanand Marg, Allahabad - 211003 (UP) first edition : 2013 Second edition : 2017 Concept / Layout Pugmarks Mediaa & Team IVF India available at: BlOSSOM FeRTIlITY & TeST TUBe BABY CeNTRe Sutaria Building, Near Bahumali Building, Nanpura, Surat - 395001, Gujarat, India Phone : 0261-2470333, 2470444, +91 99799 46222 email : info@blossomivfindia.com Website: www.blossomivfindia.com Cover: Raj Bhagat Printing: Vavo Prints, Bai-ka-Bagh, Allahabad iSBn: 978-81-932743-3-0 Price: Rs 250/- note: Contents of this booklet cannot be published elsewhere. The Opinions and contents of this booklet belongs to the doctor himself, and they are being published just to create awareness in the people. It should not be used by the patients for self diagnosis without medical advice. New therapeutics are updated due to technology and the contents of this booklet may be old or incomplete or with some errors and omissions. But purpose of this booklet is only public awareness and without Medical Ad - vice, no content of this booklet should be followed, as the composition of each patient is different, hence, it is not necessary that the content of this booklet is fit for your purpose. The patient will be responsible if this book is followed without any medical advice. If the content of this booklet is found with error or any injustice is found to be done by any one, he may kindly draw attention. -
World-Renowned Expert in Infertility Presents Findings to European
World-Renowned Expert in Infertility Presents Findings to European Conference After Two Recurrent Miscarriages, Patients Should be Thoroughly Evaluated for Risk Factors Dr. William Kutteh, M.D., one of the world’s leading researchers in recurrent pregnancy loss (RPL), was invited to present his latest discoveries to theEuropean Society of Human Reproduction and Embryology (ESHRE). Dr. Kutteh’s research on recurrent pregnancy loss calls for early intervention after the second miscarriage, a change in how physicians currently treat the condition. RPL is defined as three or more consecutive miscarriages that occur before the 20th week of pregnancy. In the general population, miscarriage occurs in 20 percent of all pregnancies, but recurrent miscarriage occurs in only 5 percent of all women seeking pregnancy. Dr. Kutteh’s study, the largest of its kind on recurrent miscarriage, scientifically proved what many physicians intrinsically knew. The 2010 study, published in Fertility and Sterility-- Diagnostic Factors Identified in 1020 Women with Two Versus Three or More Recurrent Pregnancy Losses--found that even after only two pregnancy losses, a definitive cause for RPL could be determined in two-thirds of patients in the study. Dr. Kutteh’s research showed that there was no statistical difference in women with RPL who had two pregnancy losses, and those who had three or more losses, proving that earlier intervention was appropriate. Patients with RPL are now encouraged to begin testing for known risk factors for infertility after the second miscarriage. Determining Risk Factors for Recurrent Miscarriage Recurrent miscarriage causes include anatomic, hormonal, autoimmune, infectious, genetic, or hematologic issues. Expeditiously determining the causes of miscarriage can lead to more targeted treatment, and for 67 percent of patients, a successful full-term pregnancy. -
Genetics of Recurrent and Spontaneous Miscarriage
Research and Reviews Journal of Medical and Health Science ISSN: 2319-9865 Genetics of Recurrent and Spontaneous Miscarriage Arka Dutta Gupta1* and Akash Baid2 1 Department of Human Genetics, Institute of Genetic Engineering, Madhyamgram, Badu, Itkhola, Kolkata, West Bengal 2 Department of Biotechnology, Institute of Genetic Engineering, Madhyamgram, Badu, Itkhola, Kolkata, West Bengal Research Article Received: 01/03/2017 ABSTRACT Revised: 20/03/2017 Accepted: 27/03/2017 The aim was to find out the genetic basis of recurrent spontaneous abortion (RSA) from the past pregnancies and ensure a more favourable *For Correspondence outcome in the current or future pregnancy. Pregnancy loss has always been Gupta AD, Department of Human a devastating experience for the mothers and the clinician of concern. One Genetics, Institute of Genetic out of four pregnancies ends in miscarriage. It is estimated that 50-60% of Engineering, Madhyamgram, all first trimester pregnancy losses are the cause of chromosomal Badu, Itkhola, Kolkata, West abnormality. Bengal, Tel: 8978764411. 8 couples were selected with the history of Recurrent Spontaneous fetal loss and were suggested ultrasound scan while no such abnormalities Keywords: Recurrent were found, hence further we asked for cytogenetic procedure for detection spontaneous miscarriage, Bad of chromosomal abnormalities by the method karyotyping. Obstetric History, chromosomal We discovered 45;X/46;XX, 45;X/46;XY and 46;XX/46;XY in female abnormalities partners and 46;XX/46;XY, 46;XY/47;XXY mosaicism in male partners. Two unique balanced translocations in females such as 46;XX,t(5q35:8q24) E-mail: and46;XX,t(14q:21q) and a single balanced translocation in male partner [email protected] 46;XY,t(6q:8p) with reproductive failure. -
Endometrial Immune Dysfunction in Recurrent Pregnancy Loss
International Journal of Molecular Sciences Review Endometrial Immune Dysfunction in Recurrent Pregnancy Loss Carlo Ticconi 1,*, Adalgisa Pietropolli 1, Nicoletta Di Simone 2,3, Emilio Piccione 1 and Asgerally Fazleabas 4 1 Department of Surgical Sciences, Section of Gynecology and Obstetrics, University Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy; [email protected] (A.P.); [email protected] (E.P.) 2 U.O.C. di Ostetricia e Patologia Ostetrica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A.Gemelli IRCCS, Laego A. Gemelli, 8, 00168 Rome, Italy; [email protected] 3 Istituto di Clinica Ostetrica e Ginecologica, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Rome, Italy 4 Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA; [email protected] * Correspondence: [email protected]; Tel.: +39-6-72596862 Received: 17 September 2019; Accepted: 24 October 2019; Published: 26 October 2019 Abstract: Recurrent pregnancy loss (RPL) represents an unresolved problem for contemporary gynecology and obstetrics. In fact, it is not only a relevant complication of pregnancy, but is also a significant reproductive disorder affecting around 5% of couples desiring a child. The current knowledge on RPL is largely incomplete, since nearly 50% of RPL cases are still classified as unexplained. Emerging evidence indicates that the endometrium is a key tissue involved in the correct immunologic dialogue between the mother and the conceptus, which is a condition essential for the proper establishment and maintenance of a successful pregnancy. -
Recurrent Pregnancy Loss: Diagnosis and Treatment
Medical Coverage Policy Effective Date ............................................. 2/15/2021 Next Review Date ....................................... 2/15/2022 Coverage Policy Number .................................. 0284 Recurrent Pregnancy Loss: Diagnosis and Treatment Table of Contents Related Coverage Resources Overview .............................................................. 1 Comparative Genomic Hybridization Coverage Policy ................................................... 1 (CGH)/Chromosomal Microarray Analysis (CMA) General Background ............................................ 3 for Selected Hereditary Conditions Medicare Coverage Determinations .................. 11 Genetic Testing for Reproductive Carrier Screening and Coding/Billing Information .................................. 11 Prenatal Diagnosis Hydroxyprogesterone Caproate Injection References ........................................................ 14 Immune Globulin Infertility Services INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service -
The Causes and Treatment of Recurrent Pregnancy Loss
Research and Reviews The Causes and Treatment of Recurrent Pregnancy Loss JMAJ 52(2): 97–102, 2009 Shigeru SAITO*1 Abstract Recurrent pregnancy loss is the syndrome that causes repeated miscarriage and/or stillbirth impairing the ability to have a live birth. Recently, the Japan Society of Obstetrics and Gynecology proposed screening tests for recurrent pregnancy loss and reported the frequencies of various causative factors. It has been shown that appropriate treatments after screening tests are effective in achieving a respectable rate of live births. While cases of recurrent pregnancy loss with chromosomal aberrations were previously associated with a high rate of miscarriage and inability to have a live birth, such patients can now expect to have a live baby at a probability of about 60% in the next pregnancy. It has also been shown that patients presenting no abnormality on various tests may achieve a good rate of live births without special treatment. Many couples with recurrent pregnancy loss are now given the chance of having a live birth through appro- priate screening and the best treatment available for the inferred cause. Key words Miscarriage/Stillbirth, Antiphospholipid antibodies, Coagulation factor disorder, Heparin miscarriages: 59.0%, 55.3%, 38.9%, 38.9%, and Introduction 28.6% after 2, 3, 4, 5, and 6 miscarriages, respec- tively. These clinical facts strongly suggest that an Miscarriage occurs in approximately 15% of increasing number of past miscarriages is associ- all pregnancies. When miscarriage takes place ated with further repetition of miscarriages and repeatedly 3 times or more, she is diagnosed with stillbirths attributable to factors in the mother or habitual miscarriage. -
A- Oral Presentations Medical Adjuvant Therapy Was Reviewed
Abstracts of 16th Congress of Iranian Society for Reproductive Medicine of the fibroids. Surgical methodology and use of A- Oral Presentations medical adjuvant therapy was reviewed. Results: Most of the evidence that associates 1- Infertility, Gynecology fibroids and infertility is from observational series using the patients as their own controls and from O-1 meta-analysis of these series. Myomectomy by Prognostic models in infertility any access route (laparotomy, laparoscopy, or hysteroscopy) confers subsequent pregnancy rates Al-Inani H. ranging from 10-75%. Mode of access does not Department of Obstetrics and Gynecology, Cairo seem to influence subsequent pregnancy rates. University, Giza, Egypt. Myomectomy has also been associated with a E-mail: [email protected] reduction in spontaneous pregnancy losses. Conclusion: The available evidence suggests that There is a strong need for distinction between fibroids that distort the endometrial cavity couples with a relatively good prognosis and couples (whether submucosal or intramural) appear to with poor fertility prospects. Clinical experience or adversely affect fertility and should be removed. ‗gut-feeling‘ of clinicians was the only available Further investigation is required to conclusively ‗tool‘. Comparison of the predictions made by demonstrate a cause-effect relationship. In clinicians based on clinical experience addition, the optimal surgical technique and the demonstrated a substantial reproducibility of the usefulness of adjuvant medical therapy require assessment of spontaneous conception chances, but further study. a very slight to fair reproducibility of the Key words: Fibroids, Infertility, Surgical technique. assessment of IVF-ET success rates, thereby demonstrating the need for models that predict the O-3 outcome of IVF-ET.